drugset
drugset / Trial / NCT05855083

Efficacy and Safety Study of Narsoplimab in Pediatric Patients With High-Risk Hematopoietic Stem Cell Transplant TMA

NCT05855083 ↗

Phase 2 Recruiting 18 enrolled Omeros Corporation
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety and efficacy of narsoplimab in pediatric patients with thrombotic microangiopathies (TMA) following hematopoietic stem cell transplant (HSCT).

Timeline

Start
2023-05-01
Primary completion
2025-12
Completion
2025-12

Drugs

EvaluationDrugModalityDoseRoute
Subject narsoplimab Monoclonal antibody 4 mg/kg —

Indications

disease related to hematopoietic stem cell transplant thrombotic microangiopathy